Adrenomedullin, Bcl-2 and microvessel density in normal, hyperplastic and neoplastic endometrium: Original Article

Pathology International

Volumn 59, Issue 8, 2009, Pages 530-536

  Nunobiki, Osamu ^a   Nakamura, Misa ^b   Taniguchi, Emiko ^c   Utsunomiya, Hirotoshi ^c   Mori, Ichiro ^c   Tsubota, Yukari ^d   Mabuchi, Yoshiya ^e   Kakudo, Kennichi ^c  

^a KOBE TOKIWA UNIVERSITY   (Japan)

^b OSAKA KAWASAKI REHABILITATION UNIVERSITY   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d WAKAYAMA ROSAI HOSPITAL   (Japan)

^e Department of Mabuchi Clinic ^*  (Japan)

Author keywords

Adenocarcinoma; Adrenomedullin; Bcl 2; Endometrial hyperplasia; Endometrium; Microvessel density

Indexed keywords

ADRENOMEDULLIN; PROTEIN BCL 2;

ADULT; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MICROVASCULATURE; MICROVESSEL DENSITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; VENULE;

ADENOCARCINOMA; ADRENOMEDULLIN; ADULT; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 68249148109     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2009.02403.x     Document Type: Article

References (34)

1. Nikitenko LL, MacKenzie IZ, Rees MC, Bicknell R. Adrenomedullin is an autocrine regulator of endothelial growth in human endometrium. Mol Hum Reprod 2000 6 : 811 19.
2. Kitamura K, Kanagawa K, Kawamoto M et al. Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993 192 : 553 60.
3. He H, Bessho H, Fujisawa Y et al. Effects of a synthetic rat adrenomedullin on regional hemodynamics in rats. Eur J Pharmacol 1995 273 : 209 14.
4. Kamitani S, Asakawa M, Shimekake Y, Kuwasako K, Nakahara K, Sakata T. The RAMP2/CRLR complex is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells. FEBS Lett 1999 448 : 111 14.
5. Isumi Y, Shoji H, Sugo S et al. Regulation of adrenomedullin production in rat endothelial cells. Endocrinology 1998 139 : 838 46. (Pubitemid 28510096)
6. Kato K, Yin H, Agata J, Yoshida H, Chao L, Chao J. Adrenomedullin gene delivery attenuates myocardial infarction and apoptosis after ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2003 285 : 1506 14.
7. Lu Q-L, Abel P, Foster CS, Lalani E-N. Bcl-2: Role in epithelial differentiation and oncogenesis. Hum Pathol 1996 27 : 102 10.
8. Oehler MK, Norbury C, Rees MCP, Bicknell R. Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: A possible promotion mechanism for tumour growth. Oncogene 2001 20 : 2937 45.
9. Nunobiki O, Taniguchi E, Ishii A et al. Significance of hormone receptor status and tumor vessels in normal, hyperplastic and neoplastic endometrium. Pathol Int 2003 53 : 846 52.
10. Zhao Y, Hague S, Manek S, Zhang L, Bicknell R, Rees MCP. PCR display identifies tamoxifen induction of the novel angiogenic factor adrenomedullin by a non estrogenic mechanism in the human endometrium. Oncogene 1998 16 : 409 15.
11. Mora LB, Diaz JL, Cantor AB, Nicosia SV. Differential diagnosis of endometrial hyperplasia and carcinoma by computerized image cytometry of cell proliferation, apoptosis and Bcl-2 expression. Ann Clin Lab Sci 1999 29 : 308 15.
12. Morsi HM, Leers MPG, Jager W et al. The patterns of expression of an apoptosis-related CK1 8 neoepitope, the Bcl-2 proto-oncogene, and the Ki67 proliferation marker in normal, hyperplastic, and malignant endometrium. Int J Gynecol Pathol 2000 19 : 118 26.
13. Marone M, Ferrandina G, Macchia G et al. Bcl-2, bax, bcl-XL and bcl-XS expression in neoplastic and normal endometrium. Oncology 2000 58 : 161 8. (Pubitemid 30113868)
14. Niemann TH, Trgovac TL, McGaughy VR, Vaccarello L. Bcl-2 expression in endometrial hyperplasia and carcinoma. Gynecol Qncol 1996 63 : 318 22.
15. Henderson GS, Brown KA, Perkins SL, Abbott TM, Clayton F. Bcl-2 is down regulated in atypical endometrial hyperplasia and adenocarcinoma. Mod Pathol 1996 9 : 430 38.
16. Chhieng DC, Ross JS, Ambros RA. Bcl-2 expression and the development of endometrial carcinoma. Mod Pathol 1996 4 : 402 6.
17. Chan WK, Mole MM, Levison DA et al. Nuclear and cytoplasmic Bcl-2 expression in endometrial hyperplasia and adenocarcinoma. J Pathol 1995 177 : 241 6.
18. Crescenzi E, Criniti V, Pianese M, Tecce M, Palumbo G. Differential expression of antiapoptotic genes in human endometrial carcinoma: Bcl-XL succeeds Bcl-2 function in neoplastic cells. Gynecol Oncol 2000 77 : 419 28.
19. Vairo G, Innes KM, Adams JM. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996 13 : 1511 19.
20. Wentz WB. Progestin therapy in endometrial hyperplasia. Gynecol Oncol 1974 2 : 362 7.
21. Gusberg SB, Kaplan AL. Precursors of corpus cancer. Am J Obstet Gynecol 1963 87 : 662 78.
22. Kurman RJ, Norris HJ. Endometrial neoplasia, hyperplasia and carcinoma. In : Blaustein A, ed. Pathology of the Female Genital Tract, 2nd edn. New York : Springer Verlag, 1982 311 51.
23. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: A long term study of 'untreated' hyperplasia in 170 patients. Cancer 1985 56 : 403 12.
24. Chanbers JT, Carcangiu ML, Voynick IM, Schwartz PE. Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Am J Clin Pathol 1990 94 : 255 60.
25. Sivridis E, Giatromanolaki A, Gatter KC, Harris AL, Koukourakis MI. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002 95 : 1055 63.
26. Folkman J. Angiogenesis in cancer, vascular rheumatoid and other disease. Nat Med 1995 1 : 27 31.
27. Folkman J, Klagsburn M. Angiogenic factors. Science 1987 235 : 442 7.
28. Hanahan D, Folkman J. Pattern and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1966 86 : 353 64.
29. Nicosia RF. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis? Am J Pathol 1998 153 : 11 16.
30. Shifren JL, Tseng JF, Zaloudek CJ et al. Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: Implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. Clin Endocrinol Metab 1996 81 : 3112 18.
31. Sivridis E, Giatromanolaki A, Koukourakis MI, Bicknell R, Harris AL, Gatter KC. Thymidine phosphorylase expression in normal and hyperplastic endometrium. Clin Pathol 2000 53 : 704 8.
32. Doldi N, Bassan M, Gulisano M, Broccoli V, Boncinelli E, Ferrari A. Vascular endothelial growth factor messenger ribonucleic acid expression in human ovarian and endometrial cancer. Gynecol Endocrinol 1996 6 : 375 82.
33. Nunobiki O, Sato M, Taniguchi E, Nakamura Y, Mori I, Kakudo K. Morphometric characterization of endometrial glands using quantitative cytology. Analyt Quant Cytol Histol 2001 23 : 201 6.
34. Nakamura M, Han B, Nunobiki O, Kakudo K. Adrenomedullin: A tumor progression factor via angiogenic control. Curr Cancer Drug Targets 2006 6 : 635 43.